Author:
Kim Dong-Wook,Goh Yeow-Tee,Hsiao Hui-Hua,Caguioa Priscilla B.,Kim Dongho,Kim Wan-Seok,Saikia Tapan,Agrawal Shruti,Roy Amit,Dai David,Bradley-Garelik M. Brigid,Mukhopadhyay Jaydip,Jootar Saengsuree
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Ries LAG, Melbert D, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, http://seer.cancer.gov/csr/1975_2005/ , based on November 2007 SEER data submission, posted to the SEER web site, 2008.
2. Wing YA, Priscilla BC, Chuah C, et al. Chronic myeloid leukemia in Asia. Int. J Hematol. 2009;89:14–23. doi: 10.1007/s12185-008-0230-0 .
3. Kantarjian H, Talpaz M, O’Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473–5. doi: 10.1182/blood-2002-05-1451 .
4. Druker BJ, Guilhot F, O’Brian S, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi: 10.1056/NEJMoa062867 .
5. Park SJ, Choi IK, Seo HY, et al. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Acta Haematol. 2007;118:219–21. doi: 10.1159/000111777 .
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献